UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

Clinical cancer research, 2016-04, Vol.22 (8), p.1865-1874

2016

Volltextzugriff (PDF)

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

Journal for Immunotherapy of Cancer, 2017-05, Vol.5 (1), p.44-44, Article 44

2017

Volltextzugriff (PDF)

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

Frontiers in oncology, 2023-05, Vol.13, p.1150149-1150149

2023

Volltextzugriff (PDF)

Foxp3 expression in human cancer cells

Journal of translational medicine, 2008-04, Vol.6 (1), p.19-19, Article 19

2008

Volltextzugriff (PDF)

A Monoclonal Cytolytic T-Lymphocyte Response Observed in a Melanoma Patient Vaccinated with a Tumor-Specific Antigenic Peptide Encoded by Gene MAGE-3

Proceedings of the National Academy of Sciences - PNAS, 2001-08, Vol.98 (18), p.10290-10295

2001

Volltextzugriff (PDF)

Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma

Clinical cancer research, 2006-02, Vol.12 (3), p.869-877

2006

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges

Journal for immunotherapy of cancer, 2020-12, Vol.8 (2), p.e001472

2020

Volltextzugriff (PDF)

Foxp3 Expression in Liver Correlates with the Degree but Not the Cause of Inflammation

Mediators of Inflammation, 2011-01, Vol.2011 (2011), p.388-396

2011

Volltextzugriff (PDF)

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

Nature medicine, 2018-07, Vol.24 (7), p.994-1004

2018

Volltextzugriff (PDF)

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

Science translational medicine, 2020-03, Vol.12 (534)

2020

Volltextzugriff (PDF)

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Clinical cancer research, 2016-07, Vol.22 (13), p.3286-3297

2016

Volltextzugriff (PDF)

Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation

Clinical cancer research, 2021-08, Vol.27 (15), p.4147-4159

2021

Volltextzugriff (PDF)

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

Cancer immunology research, 2015-12, Vol.3 (12), p.1344-1355

2015

Volltextzugriff (PDF)

CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.6291-6292

2022

Volltextzugriff (PDF)

Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies

Clinical cancer research, 2024-04, Vol.30 (8), p.1448-1456

2024

Volltextzugriff (PDF)

Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy

Cancer biology & therapy, 2008-03, Vol.7 (3), p.345-352

2008

Volltextzugriff (PDF)

Flow Cytometric Measurement of Intracellular Cytokines Detects Immune Responses in MUC1 Immunotherapy

Clinical cancer research, 2000-03, Vol.6 (3), p.829-837

2000

Volltextzugriff (PDF)

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

Theranostics, 2022, Vol.12 (3), p.1373-1387

2022

Volltextzugriff (PDF)

Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects

Journal of experimental & clinical cancer research, 2010-06, Vol.29 (1), p.64-64, Article 64

2010

Volltextzugriff (PDF)

Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer

Cancer biology & therapy, 2007-08, Vol.6 (8), p.1269-1268

2007

Volltextzugriff (PDF)

Tumor immune escape mediated by indoleamine 2,3-dioxygenase

Immunology Letters, 2007-08, Vol.111 (2), p.69-75

2007

Volltextzugriff (PDF)

Determinants of cancer immunotherapy success

Expert review of vaccines, 2010-12, Vol.9 (12), p.1363-1366

2010

Volltextzugriff (PDF)

Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.4553-4553

2020

Volltextzugriff (PDF)

Abstract 1494: Combination of CEA TCB, a novel T-cell bispecific antibody for the treatment of solid tumors, with PD-L1 checkpoint blockade

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.1494-1494

2016

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(56)

Publikationsform

Artikel
(64)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(44)
Humans
(41)
Oncology
(25)
Immunology
(24)
Immunotherapy
(20)
Female
(15)
Aged
(14)
Male
(14)
T-Lymphocytes, Cytotoxic - Immunology
(14)
Middle Aged
(12)
Lung Neoplasms - Immunology
(11)
Cancer
(10)
Animals
(9)
Biological And Medical Sciences
(9)
Immunotherapy - Methods
(9)
Medical Sciences
(9)
T-Lymphocytes - Immunology
(9)
Tumors
(9)
Adult
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

Foxp3 expression in human cancer cells

Phase 1, first-in-human study of TYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager, in metastatic melanoma: active drug monitoring to assess the impact of immune response on drug exposure

A Monoclonal Cytolytic T-Lymphocyte Response Observed in a Melanoma Patient Vaccinated with a Tumor-Specific Antigenic Peptide Encoded by Gene MAGE-3

Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges

Foxp3 Expression in Liver Correlates with the Degree but Not the Cause of Inflammation

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

CD25 Targeting Eliminates Regulatory T Cells and CD25+ Blasts in Acute Myeloid Leukemia

Facts and Hopes on Biomarkers for Successful Early Clinical Immunotherapy Trials: Innovative Patient Enrichment Strategies

Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy

Flow Cytometric Measurement of Intracellular Cytokines Detects Immune Responses in MUC1 Immunotherapy

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects

Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer

Tumor immune escape mediated by indoleamine 2,3-dioxygenase

Determinants of cancer immunotherapy success

Abstract 4553: The CD25 antibody RG6292 selectively depletes Tregs while preserving IL-2 signaling and CTL activity for tumor control

Abstract 1494: Combination of CEA TCB, a novel T-cell bispecific antibody for the treatment of solid tumors, with PD-L1 checkpoint blockade

Suchergebnisse filtern